Adamis Pharmaceuticals (NASDAQ:ADMP) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Adamis Pharmaceuticals (NASDAQ:ADMPGet Rating) in a note issued to investors on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, Zacks Investment Research lowered shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 19th.

Shares of ADMP opened at $0.44 on Thursday. Adamis Pharmaceuticals has a fifty-two week low of $0.42 and a fifty-two week high of $1.48. The firm has a 50 day moving average price of $0.57 and a 200-day moving average price of $0.70.

Adamis Pharmaceuticals (NASDAQ:ADMPGet Rating) last announced its quarterly earnings data on Thursday, March 31st. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.02). Adamis Pharmaceuticals had a negative return on equity of 85.31% and a negative net margin of 458.77%. During the same quarter in the prior year, the business earned ($0.16) earnings per share. Equities research analysts expect that Adamis Pharmaceuticals will post -0.13 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC increased its stake in shares of Adamis Pharmaceuticals by 9.6% in the fourth quarter. Virtu Financial LLC now owns 224,561 shares of the specialty pharmaceutical company’s stock worth $136,000 after buying an additional 19,691 shares during the period. Avantax Advisory Services Inc. increased its stake in shares of Adamis Pharmaceuticals by 68.8% in the fourth quarter. Avantax Advisory Services Inc. now owns 54,000 shares of the specialty pharmaceutical company’s stock worth $33,000 after buying an additional 22,000 shares during the period. Geode Capital Management LLC increased its stake in shares of Adamis Pharmaceuticals by 3.7% in the third quarter. Geode Capital Management LLC now owns 1,333,913 shares of the specialty pharmaceutical company’s stock worth $1,293,000 after buying an additional 47,774 shares during the period. Atom Investors LP purchased a new position in shares of Adamis Pharmaceuticals in the third quarter worth $55,000. Finally, Capital CS Group LLC purchased a new position in shares of Adamis Pharmaceuticals in the first quarter worth $40,000. 10.14% of the stock is currently owned by institutional investors.

About Adamis Pharmaceuticals (Get Rating)

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose.

See Also

Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.